{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:04:13Z","timestamp":1789502653672,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.clml.2023.12.008","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T08:13:43Z","timestamp":1703060023000},"page":"260-268.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes"],"prefix":"10.1016","volume":"24","author":[{"given":"Nishanthan","family":"Rajakumaraswamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitul","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Sallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naval G.","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyuan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahed","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Karalliyadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4861-1897","authenticated-orcid":false,"given":"Yunfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paresh","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.12.008_bib0001","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2147\/JBM.S12257","article-title":"Myelodysplastic syndromes\/neoplasms: recent classification system based on World Health Organization classification of tumors\u2014International Agency for Research on Cancer for hematopoietic and lymphoid tissues","volume":"1","author":"Gupta","year":"2010","journal-title":"J Blood Med"},{"issue":"1","key":"10.1016\/j.clml.2023.12.008_bib0002","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13045-022-01346-9","article-title":"Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease","volume":"15","author":"Mohty","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.clml.2023.12.008_bib0003","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2023.12.008_bib0004","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.V84.9.3148.3148","article-title":"p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies","volume":"84","author":"Wattel","year":"1994","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.12.008_bib0005","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.12203","article-title":"TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis","volume":"160","author":"Kulasekararaj","year":"2013","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2023.12.008_bib0006","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clml.2023.12.008_bib0007","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.12.008_bib0008","article-title":"Resistance to hypomethylating agents in myelodysplastic syndrome and acute myeloid leukemia from clinical data and molecular mechanism","volume":"11","author":"Zhao","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.clml.2023.12.008_bib0009","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/cts.12972","article-title":"Asia-inclusive global development of pevonedistat: clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial","volume":"14","author":"Zhou","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"6","key":"10.1016\/j.clml.2023.12.008_bib0010","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2018-03-785915","article-title":"How I treat MDS after hypomethylating agent failure","volume":"133","author":"Santini","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2023.12.008_bib0011","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/bjh.15273","article-title":"Azacitidine in the 'real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome\/low blast count acute myeloid leukaemia patients in Ontario, Canada","volume":"181","author":"Mozessohn","year":"2018","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2023.12.008_bib0012","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clml.2022.11.002","article-title":"Azacitidine monotherapy in patients with treatment-naive higher-risk myelodysplastic syndrome: a systematic literature review and meta-analysis","volume":"23","author":"Hasegawa","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.clml.2023.12.008_bib0013","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/leu.2015.115","article-title":"Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry","volume":"29","author":"Bernal","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.12.008_bib0014","unstructured":"National Technical Information Services. Limited access death master file download. Available at: https:\/\/dmf.ntis.gov\/index.php. Accessed: April 28, 2023."},{"issue":"2","key":"10.1016\/j.clml.2023.12.008_bib0015","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/cam4.3608","article-title":"Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium","volume":"10","author":"Komrokji","year":"2021","journal-title":"Cancer Med."},{"issue":"4","key":"10.1016\/j.clml.2023.12.008_bib0016","first-page":"1121","article-title":"Clinical endpoints in oncology\u2014a primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"2","key":"10.1016\/j.clml.2023.12.008_bib0017","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2023.12.008_bib0018","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","article-title":"Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML","volume":"6","author":"Ad\u00e8s","year":"2022","journal-title":"Blood Adv"},{"issue":"36","key":"10.1016\/j.clml.2023.12.008_bib0019","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.2217\/fon-2021-0936","article-title":"Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?","volume":"17","author":"Zeidan","year":"2021","journal-title":"Future Oncol"},{"issue":"7","key":"10.1016\/j.clml.2023.12.008_bib0020","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood-2016-02-700054","article-title":"Time-dependent changes in mortality and transformation risk in MDS","volume":"128","author":"Pfeilst\u00f6cker","year":"2016","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.clml.2023.12.008_bib0021","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.3390\/cancers14194941","article-title":"Novel therapies for unmet clinical needs in myelodysplastic syndromes","volume":"14","author":"Cassanello","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T20:36:57Z","timestamp":1729111017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023021973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2152265023021973"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.12.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}